ZEO ScientifiX SEC Filings

Zeo ScientifiX, Inc. reported an insider equity award for its CEO, CFO and director Ian T. Bothwell. On 01/14/2026, he received 175,000 shares of common stock at a price of $0 per share as a grant of restricted stock under the company’s 2021 Equity Incentive Plan. These shares vest in two equal parts, with 50% vesting on the 8th month anniversary of the grant date and the remaining 50% vesting on the 12th month anniversary. Following this transaction, Bothwell beneficially owned 915,094 shares of Zeo ScientifiX common stock held directly.

Zeo ScientifiX, Inc. reported that Chief Medical Officer and director George Craig Shapiro received a grant of 175,000 shares of common stock on 01/14/2026. The filing shows this as an acquisition at a price of $0 per share, reflecting a restricted stock award under the company’s 2021 Equity Incentive Plan.

According to the terms, the restricted shares vest 50% on the 8th month anniversary of the grant date and the remaining 50% on the 12th month anniversary. Following this equity grant, Shapiro beneficially owns 578,021 shares of Zeo ScientifiX common stock in direct ownership.

Zeo ScientifiX, Inc. reported that it has entered into a comprehensive strategic partnership with Cytora Therapeutics Ltd. and Made Scientific, Inc. The collaboration focuses on advancing and commercializing Cytora’s novel allogeneic, off-the-shelf human oral mucosal stem cell therapy in the United States.

Cytora is described as a clinical-stage biotechnology company based in Israel, while Made Scientific is a U.S.-based cell therapy contract development and manufacturing organization. The joint press release outlining additional details of the partnership is attached as Exhibit 99.1.

Zeo ScientifiX, Inc. announced a leadership change, making Ian T. Bothwell the company’s full-time Chief Executive Officer effective December 24, 2025. He had been serving as Interim Chief Executive Officer while also holding the role of Chief Financial Officer, and will continue in the dual position of Chief Executive Officer and Chief Financial Officer. This move formalizes the company’s executive leadership structure by confirming Bothwell as permanent CEO.

Zeo ScientifiX, Inc. reported that, effective November 30, 2025, it terminated the employment of Ron Borsheim as its Chief Sales Officer – Aesthetics. The company identifies itself as a Nevada corporation with principal offices in Davie, Florida, and it currently has no securities listed on a national securities exchange. The report is signed by Interim Chief Executive Officer and Chief Financial Officer Ian T. Bothwell, indicating executive-level oversight of this leadership change.

Zeo ScientifiX, Inc. filed an 8-K reporting that on October 23, 2025 it issued a press release stating the company is prepared to capitalize on the potentially rapid expansion of Florida’s regenerative medicine market following enactment of the new state stem cell law, SB 1768, effective July 1, 2025.

The press release is furnished as Exhibit 99.1 and incorporated by reference.

Zeo ScientifiX, Inc. (ZEOX) filed a Form 10-Q showing constrained liquidity and a continuing operations focus on clinical and commercial support. The company reported $4,706,000 for the nine months ended July 31, 2025, used $335,000 of cash in operating activities in that period, and had a stockholders’ deficit of $2,314,000 at July 31, 2025. The balance sheet shows multiple finance leases entered into in June 2025 for equipment (one with 60 monthly payments of $1,600 at 2.7% and one with 36 monthly payments of $500 at 8.0%), and a recent asset purchase of BIO assets with a $200,000 purchase price largely allocated to inventory.

Capital structure items include $725,000 of convertible debt (convertible into up to 120,834 shares), significant stock-based compensation and warrant grants (including grants with a $1,428,000 fair value for warrants), and 263,333 unvested restricted shares (178,333 unissued). Revenue concentration is notable, with single customers representing double-digit percentages of revenues in multiple periods. The filing discloses commissions earned under a Sales Agreement ($62,000 for nine months ended July 31, 2025) and related-party product sales to an MSO tied to the Chief Medical Officer.